KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest & Investment Income: 2018-2024

Historic Interest & Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $47.3 million.

  • Royalty Pharma's Interest & Investment Income fell 60.57% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year decrease of 20.64%. This contributed to the annual value of $47.3 million for FY2024, which is 34.51% down from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Interest & Investment Income is $47.3 million, which was down 34.51% from $72.3 million recorded in FY2023.
  • Royalty Pharma's Interest & Investment Income's 5-year high stood at $78.3 million during FY2022, with a 5-year trough of $28.4 million in FY2020.
  • For the 3-year period, Royalty Pharma's Interest & Investment Income averaged around $66.0 million, with its median value being $72.3 million (2023).
  • Per our database at Business Quant, Royalty Pharma's Interest & Investment Income soared by 88.64% in 2021 and then slumped by 34.51% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Interest & Investment Income stood at $28.4 million in 2020, then spiked by 88.64% to $53.5 million in 2021, then surged by 46.32% to $78.3 million in 2022, then fell by 7.72% to $72.3 million in 2023, then slumped by 34.51% to $47.3 million in 2024.